Article

Two-Drug Combo Improves Post-Transplant Myeloma Outcomes

A two-drug regimen improved outcomes for patients with myeloma when given before a stem cell transplant.

Loretta Williams, PhD, APRN, AOCN, OCN, of the University of Texas MD Anderson Cancer Center, discusses the importance of communication between patient and provider when deciding on a treatment regimen for multiple myeloma, where side effects and outcomes are both considered.

Williams recently led a study that showed that when given before a autologous hematopoietic stem cell transplant, the two-drug regimen of busulfan plus melphalan had better progression-free survival rates than melphalan alone. However, the combination also came with higher rates of side effects (including mouth and throat pain) for the month after treatment. These side effects eventually decreased as time went on, leading Williams to believe that this is a viable pre-treatment strategy for eligible patients.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Dr. Valerie Lee discussed emerging targeted therapies and personalized medicine approaches that are showing promise for those with gastrointestinal cancer.
Image of doctor.
Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease.
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Related Content